Inhibrx Inc

NASDAQ:INBX   3:59:50 PM EDT
36.33
-2.13 (-5.54%)
Products

Inbrx-101 Shows Favorable Safety Profile In Patients With Alpha-1 Antitrypsin Deficiency

Published: 10/12/2021 11:39 GMT
Inhibrx Inc (INBX) - Inbrx-101 Shows Favorable Safety Profile in Patients With Alpha-1 Antitrypsin Deficiency and Demonstrates the Potential to Achieve Normal Alpha-1 Antitrypsin Levels With Monthly Dosing.
Inhibrx Inc - Interim Results From Phase 1 Study Show a Favorable Safety and Tolerability Profile.
Inhibrx Inc - Data From Single Ascending Dose Cohorts at 10, 40, 80 and 120 Mg/kg Revealed Potential to Achieve Normal Aat Levels With Monthly Dosing.
Inhibrx Inc - Data From First Multiple Ascending Dose Cohort at 40 Mg/kg Iv Every Three Weeks Showed Expected Accumulation of Functional Aat Levels.
Inhibrx Inc - No Drug-related Severe Or Serious Adverse Events at Doses Up to and Including 120 Mg/kg Single Dose and 80mg/kg Multi-dose.